Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study

Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study

<p>Abstract</p> <p>Background</p> <p>Arsenic Trioxide (ATO) is effective in about 20% of patients with myelodysplasia (MDS); its mechanisms of action have already been evaluated in vitro, but the in vivo activity is still not fully understood. Since ATO induces apoptosi...

Full description

Bibliographic Details
Main Authors: Galimberti Sara, Guerrini Francesca, Salvi Flavia, Petrini Iacopo, Gioia Daniela, Messa Emanuela, Palumbo Giuseppe A, Cilloni Daniela, Petrini Mario, Levis Alessandro
Format: Article
Language:English
Published: BMC 2012-09-01
Series:Journal of Hematology & Oncology
Subjects:
ATO
Ascorbic acid
Myelodysplastic syndromes
MDS
Apoptosis
Online Access:http://www.jhoonline.org/content/5/1/53

Internet

http://www.jhoonline.org/content/5/1/53

Similar Items